ProQR Therapeutics
PRQR
44 hedge funds and large institutions have $161M invested in ProQR Therapeutics in 2020 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 19 reducing their positions, and 11 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.65% less ownership
Funds ownership: 61.07% → 59.42% (-1.6%)
14% less funds holding
Funds holding: 51 → 44 (-7)
26% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 19
45% less call options, than puts
Call options by funds: $80K | Put options by funds: $146K
46% less capital invested
Capital invested by funds: $299M → $161M (-$138M)
64% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$3.67M |
| 2 |
CAC
Cowen and Company
New York
|
+$1.93M |
| 3 |
Morgan Stanley
New York
|
+$1.55M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$947K |
| 5 |
JP Morgan Chase
New York
|
+$677K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.52M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.22M |
| 4 |
Millennium Management
New York
|
-$2.16M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$786K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EMG
51
Ellington Management Group
Old Greenwich,
Connecticut
| – | -$151K | -15,200 | Closed |
|
52
Walleye Capital
New York
| – | -$113K | -11,393 | Closed |
|
53
ProShare Advisors
Bethesda,
Maryland
| – | -$106K | -10,675 | Closed |
|
54
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$36K | -3,645 | Closed |
|
55
Bank of America
Charlotte,
North Carolina
| – | -$2K | -232 | Closed |
|
PRQR Hedge Fund Activity: Q1 2020 in Review
44 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q1 2020, worth a combined $161M — down 46% from $299M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of PRQR and 4 opened new positions — a net loss of 7 holders — while 19 trimmed existing stakes and 14 added.
The largest buyer was Aquilo Capital Management, adding an estimated $3.67M. The largest seller was Sphera Funds Management, cutting an estimated $3.52M.
- 44 institutional investors held ProQR Therapeutics (PRQR) as of Q1 2020, down from 51 in Q4 2019.
- Funds reported $161M of ProQR Therapeutics stock for Q1 2020, down 46% quarter-over-quarter.
- 4 funds opened new ProQR Therapeutics positions in Q1 2020 and 11 closed out, a net change of -7 holders.
- The largest ProQR Therapeutics buyer in Q1 2020 was Aquilo Capital Management, an estimated $3.67M added.
- The largest ProQR Therapeutics seller in Q1 2020 was Sphera Funds Management, an estimated $3.52M sold.
Based on aggregated 13F filings for Q1 2020.